Print Page  Close Window

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
09/12/17NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation
REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, announced that at NeuroDerm’s extraordinary general meeting of shareholders held today, NeuroDerm shareholders voted to approve the previously announced acquisition by Mitsubishi Tanabe Pharma Corporation (TSE Code: 4508), a publicly traded company on the Tokyo Stock Exchange (“MTPC”), and all t... 
Printer Friendly Version
08/03/17NeuroDerm Announces Second Quarter 2017 Financial Results
REHOVOT, Israel, Aug. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for the second quarter ended June 30, 2017. Recent Highlights On July 24, 2017, NeuroDerm entered into a definitive agreement to be acquired by Mitsubishi Tanabe Pharma Corporation (MTPC) for US$1.1 billion in cash. A special meeting of shareholders to ap... 
Printer Friendly Version
08/01/17NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation
REHOVOT, Israel, Aug. 01, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will hold an extraordinary general meeting of shareholders on Tuesday, September 12, 2017, at 3:00 p.m., Israel time, at the principal executive offices of NeuroDerm, located at 3 Pekeris Street, Rabin Science Park, Rehovot 7670212, Israel at which NeuroDerm’s prospective ... 
Printer Friendly Version
07/24/17NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
REHOVOT, Israel – July 24, 2017 – NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it has signed a definitive agreement under which Mitsubishi Tanabe Pharma Corporation (TSE Code: 4508) (“MTPC”), a publicly traded company on the Tokyo Stock Exchange, will acquire NeuroDerm for US$39 per share in cash. The transaction has received unanimous approval by NeuroDerm’s Bo... 
Printer Friendly Version
06/27/17Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology
-Complete reduction of OFF-time to zero in 42% of patients treated for 24 hours; statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients ON by 8:00am- REHOVOT, Israel, June 27, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that Werner Poewe, Professor of Neurology and Director of the Departm... 
Printer Friendly Version
06/08/17NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders
Includes demographic data from the ND0612 trial 006 and complete data from a Phase 1 pharmacokinetic study of ND0701 REHOVOT, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will present six posters related to its clinical pipeline in a poster session today from 1:15 p.m. to 2:45 p.m. PT at the 21st International Congress of Pa... 
Printer Friendly Version
06/06/17European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial
REHOVOT, Israel, June 06, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it has received a Scientific Advice Letter from the Scientific Advice Working Party of the European Medicines Agency (EMA). The letter accepts the main design elements suggested by NeuroDerm for the amended iNDiGO phase III efficacy trial (trial 007), including study populati... 
Printer Friendly Version
06/05/17NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
-ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated for 24 hours - - Statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients "ON" by 8:00am- REHOVOT, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced final data from trial 006.  Sheila Oren, MD,... 
Printer Friendly Version
05/30/17NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017
REHOVOT, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that CEO Oded S. Lieberman, PhD will present at the Jefferies Global Healthcare Conference on Wednesday, June 7 at 2:30 pm ET in New York.  Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkin... 
Printer Friendly Version
05/23/17NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - - ND0612 clinical data featured in four additional abstracts - REHOVOT, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congre... 
Printer Friendly Version
05/11/17NeuroDerm Announces First Quarter 2017 Financial Results
REHOVOT, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for the first quarter ended March 31, 2017. “We are pleased with our continued clinical progress for our lead product candidates, and remain on track to achieve our anticipated milestones for ND0612 and ND0701,” stated Oded Lieberman, PhD, CEO of NeuroDerm. “Ou... 
Printer Friendly Version
04/20/17NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
REHOVOT, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that the company’s CEO, Oded S. Lieberman, PhD, will ring The Nasdaq Stock Market Opening Bell in New York on Friday, April 21, 2017. A live stream of the ceremony will be available at http://livestream.com/nasdaq/live from approximately 9:15 a.m. ET until 9:30 a.m. ET. Neuro... 
Printer Friendly Version
04/10/17NeuroDerm to Host Investor Day on April 21, 2017
REHOVOT, Israel, April 10, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that the Company will host its first Investor Day, taking place in New York on Friday, April 21, 2017. Members of NeuroDerm’s executive team will be joined by key opinion leaders to review the company’s clinical programs for treating patients with moderate and severe Parkinson... 
Printer Friendly Version
03/30/17NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results
Files Annual Report on Form 20-F Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for the fourth quarter and 2016 fiscal year ended December 31, 2016, and has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 wit... 
Printer Friendly Version
03/21/17NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017
REHOVOT, Israel, March 21, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will report financial results for the fourth quarter and fiscal year of 2016 before the market opens on Thursday, March 30, 2017. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To acce... 
Printer Friendly Version
03/01/17NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting
- Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in proportion of patients “ON” by 8:00 am (primary and key secondary endpoints) - - The trial also showed statistically significant reduction in troublesome dyskinesia and a complete reduction of OFF-time to zero hours in 66% of responders (post hoc sub-groups analyses) - - Company to host conference call and webcast today at 8:30 a.m. ET- REHOVOT, Israel, March 01, 2017 (GL... 
Printer Friendly Version
02/27/17NeuroDerm CEO to Present at Upcoming Investor Conferences
REHOVOT, Israel, Feb. 27, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences: Cowen and Company 37th Annual Health Care Conference taking place in Boston, Massachusetts from March 6 – 8, 2017.  Dr. Lieberman’s presentation will take place on Monday, March 6 at 2:00pm ET. 29th Annual R... 
Printer Friendly Version
01/26/17NeuroDerm Announces Extraordinary General Meeting of Shareholders
REHOVOT, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold an extraordinary general meeting of shareholders on Thursday, March 2, 2017 for the purposes of approving certain compensatory matters that require shareholder approval under the Israeli Companies Law. The agenda items for the meeting consist of: (i) approval of an option grant and ... 
Printer Friendly Version
01/03/17NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017
REHOVOT, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 10:30 am PT / 1:30 pm ET in San Francisco.  Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to sev... 
Printer Friendly Version